Beta-CGRP: rat nerve signaling peptide (beta-calcitonin gene-related peptide)
A natural nerve-signal molecule found in rats that helps relay pain and widens blood vessels; used only as a laboratory research tool.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
Beta-CGRP (β-calcitonin gene-related peptide) is a 37-residue neuropeptide produced naturally in the rat brain and thyroid. It belongs to the calcitonin family of peptides — a group that also includes α-CGRP, amylin, adrenomedullin, and calcitonin itself — all of which act through related class B G protein-coupled receptors (Hay and colleagues, British Journal of Pharmacology, 2018). The β-CGRP gene is distinct from the α-CGRP gene; the two rat peptides differ by a single amino acid, and β-CGRP appears to be the sole mature transcript its gene produces (Amara and colleagues, Science, 1985). The stored sequence represents the rat β-CGRP backbone; like all CGRP family members, the active peptide contains a disulfide bond between the two cysteines at positions 1 and 7 (forming a ring at the N-terminus), a structural feature not visible in the linear sequence.
History
The discovery of β-CGRP arose directly from the earlier finding that a single rat gene could, through alternative RNA processing, produce either calcitonin or α-CGRP. In 1985, Amara and colleagues identified an mRNA in rat brain and thyroid that encoded a novel peptide homologous to α-CGRP but differing by one residue — naming it β-CGRP. Hybridization histochemistry showed a similar anatomical distribution of α- and β-CGRP transcripts in brain tissue (Amara and colleagues, Science, 1985). The finding established that the calcitonin gene family was larger than previously recognized and that alternative splicing could diversify neuropeptide signaling at a single genomic locus. Subsequent decades of pharmacological work clarified that the biological differences between α- and β-CGRP are subtle, and the two forms share receptor targets within the calcitonin/CGRP receptor family.
What it does
β-CGRP acts through receptors assembled from the calcitonin receptor (CTR) or the calcitonin receptor-like receptor (CLR) combined with receptor activity-modifying proteins (RAMPs). This combinatorial assembly generates a family of pharmacologically distinct receptor complexes — including the canonical CGRP receptor (CLR/RAMP1), the amylin receptors (AMY1, AMY2, AMY3: CTR combined with RAMP1, RAMP2, or RAMP3 respectively), and the adrenomedullin receptors — each with different ligand preferences (Hay and colleagues, 2018; Barwell and colleagues, British Journal of Pharmacology, 2012). β-CGRP's assignment to the calcitonin receptor (CTR) reflects its activity at CTR-containing amylin receptor complexes, which has attracted research interest in the context of metabolic signaling. The calcitonin/CGRP receptor family has therapeutic relevance across multiple conditions including migraine, osteoporosis, diabetes, obesity, and cardiovascular disease (Barwell and colleagues, 2012).
Evidence
- Human: β-CGRP itself (the rat peptide) has not been tested in human clinical trials. Its close human analog α-CGRP and the broader CGRP receptor system have been extensively studied in migraine and cardiovascular contexts; β-CGRP serves primarily as a pharmacological probe.
- Animal: Identified and localized in rat brain and thyroid by hybridization histochemistry (Amara and colleagues, 1985). The pharmacology of rat α- and β-CGRP at CTR and CLR receptor complexes has been characterized in cell-based and tissue systems (Lee and colleagues, Journal of Biological Chemistry, 2016).
- In vitro: Peptide interaction mechanisms at the calcitonin receptor and amylin receptor complexes have been studied at the molecular level; RAMPs function as allosteric modulators that reshape the pharmacological profile of CTR and CLR (Advances in Pharmacology, 2020; Lee and colleagues, 2016).
Known effects
- Receptor activation at CTR/RAMP complexes (amylin receptors) — Mechanistic; characterized in cell-based studies (Lee and colleagues, 2016)
- Neuropeptide expression in brain and thyroid — Demonstrated by hybridization histochemistry in rat (Amara and colleagues, 1985)
- RAMP-dependent pharmacological diversification — Mechanistic; CTR heterodimerization with RAMP1/2/3 generates receptor subtypes with distinct ligand selectivity profiles (Hay and colleagues, 2018; Advances in Pharmacology, 2020)
Mechanism
β-CGRP signals through class B GPCRs whose pharmacology is substantially reshaped by receptor activity-modifying proteins (RAMPs). The calcitonin receptor (CTR) on its own responds preferentially to calcitonin and amylin; when CTR heterodimerizes with RAMP1, RAMP2, or RAMP3, it generates the AMY1, AMY2, or AMY3 receptor subtypes, which respond with different affinities to calcitonin, amylin, α-CGRP, and β-CGRP (Hay and colleagues, 2018). This RAMP-dependent diversification means that β-CGRP's biological effects depend critically on which RAMP is expressed in a given tissue. RAMPs also function as allosteric modulators, influencing both ligand docking and receptor activation beyond simply changing selectivity (Advances in Pharmacology, 2020). Separately, CLR combined with RAMP1 constitutes the canonical CGRP receptor. The calcitonin receptor itself — in osteoclasts, where it is strongly expressed — mediates classical calcitonin effects on bone resorption (Granholm and colleagues, Journal of Cellular Biochemistry, 2008; Davey and colleagues, Journal of Bone and Mineral Research, 2013), though this osteoclast role applies more directly to calcitonin and amylin than to CGRP peptides.
Related peptides
- α-CGRP — the other product of the rat calcitonin gene locus (via alternative RNA processing), differing from β-CGRP by a single amino acid; shares the same receptor targets
- Amylin — fellow calcitonin-family member; acts at the same CTR/RAMP amylin receptor complexes; the amylin-receptor agonism component of cagrilintide (part of CagriSema) involves the same receptor system as β-CGRP (Hay and colleagues, 2018)
- Calcitonin — the classical ligand for CTR; bone biology anchor of this receptor family; see the calcitonin receptor family review (Barwell and colleagues, 2012)
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Does the negative charge at position 25 of rat beta-CGRP make it selectively activate one variant of the CGRP receptor over others?
If confirmed, rat beta-CGRP could become a natural research tool for studying specific receptor variants, reducing the need to synthesise artificial peptide probes and accelerating discovery of drugs targeting individual receptor subtypes.
Does beta-CGRP act specifically in the thyroid to stimulate calcitonin release and protect bone density?
If confirmed, a drug that mimics beta-CGRP's thyroid-specific action could boost calcitonin production to protect against osteoporosis, without the blood-pressure-lowering vascular effects that make full CGRP agonists difficult to use safely.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.7218682765960693 | openfold3-mlx |
| ranking score | 0.8379042148590088 | openfold3-mlx |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 0.892 | global PDE — lower = better |
| disorder | 0.249 | fraction disordered |
| chain pair ipTM (A, B) | 0.722 | interface quality |
▸3-letter notation
▸recipeopenfold3-mlx 0.3.1
| parameter | value |
|---|---|
| model | openfold3-mlx 0.3.1 |
| weights | aedd8f3eb814e392… |
| hardware | apple_m4_base_16gb |
| mlx version | 0.31.1 |
| python | 3.14.3 |
| random seed | 42 |
| msa strategy | colabfold |
| diffusion samples | 1 |
| runtime | 461s |
| predicted by | mlx@peptide |
| predicted at | 2026-04-24 |
python3 openfold3/run_openfold.py predict --query_json {query.json} --runner_yaml examples/example_runner_yamls/mlx_runner.yml --output_dir {output_dir} --num_diffusion_samples 1 ▸citationbibtex
@peptide{pep10644,
sequence = {SCNTATCVTHRLAGLLSRSGGVVKDNFVPTNVGSKAF},
target = {calcr},
author = {peptidemodel},
year = {2026},
status = {synthesized}
}